
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Protagonist Therapeutics, retaining the price target of $190.00. Evan Seigerman has given his Buy rating due to a combination
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics | 125.15 | 40.44 | 47.73% |
| Name | Price | % Change | |
|---|---|---|---|
| $125.15 | +47.73% |

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Protagonist Therapeutics, retaining the price target of $190.00. Evan Seigerman has given his Buy rating due to a combination

JPMorgan raised the firm’s price target on Protagonist Therapeutics (PTGX) to $151 from $149 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source

Reports Q3 revenue $274.41M, consensus $241.32M. “The third quarter was a defining period for Protagonist, with FDA approval of MIMRYLO, our second approval this year for a first-in-class peptide drug,

UBS analyst Alice Nettleton has maintained their bullish stance on PTGX stock, giving a Buy rating on October 21. Alice Nettleton’s Buy rating is based on the promising commercial opportunity

TD Cowen analyst Tara Bancroft raised the firm’s price target on Protagonist Therapeutics (PTGX) to $160 from $155 and keeps a Buy rating on the shares. The firm updated its

Leerink assumed coverage of Protagonist Therapeutics (PTGX) with an Outperform rating and $190 price target The firm believes Protagonist offers a rare setup in biotech, as two approvals have de-risked

UBS initiated coverage of Protagonist Therapeutics (PTGX) with a Buy rating and $184 price target The firm sees “underappreciated commercial potential” for PN-881, which it views as Protagonist’s most important

Biotech Analyst Zhong, along with Philip J. Mease, MD, of the University of Washington School of Medicine, discuss the positioning of emerging IL-17 candidates in the treatment process for either

Protagonist Therapeutics (PTGX) announced that its board of directors has authorized a share repurchase program under which the company may repurchase up to $300M of its outstanding common stock. The

Protagonist Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Richard Law CFA from Goldman Sachs maintained a Buy rating on the stock and has
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Assigned | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Oct 21, 2026 | ||||
| buy | Reiterated | Oct 15, 2026 | ||||
| buy | Initiated | Oct 12, 2026 | ||||
| buy | Reiterated | Sep 1, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 2, 2027TBA | $8.14B | $-0.13 | $45.42M | 0.29 | 24.09 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.